Bellerophon Therapeutics, Inc.
DelistedCIK 1600132fmd_0KJ6VVRBBNGGNPSG9VMJJ50QNAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2023, 41 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 53 | 46 | 33 | 17 | 18 | 20 | 11 | 18 | 13 | 16 |
| Total operating expenses | 62 | 60 | 48 | 24 | 25 | 28 | 17 | 26 | 20 | 22 |
| Operating income | (62) | (60) | (47) | (24) | (25) | (28) | (17) | (26) | (20) | (22) |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Other non-operating income (expense) | – | – | – | – | – | 0 | 0 | (0) | 0 | 0 |
| Income before taxes | (62) | (60) | (46) | (24) | (55) | (3) | (15) | (27) | (20) | (22) |
| Income tax expense | 0 | 0 | 0 | (0) | 0 | (5) | (2) | (2) | (2) | (2) |
| Net income from continuing operations | (62) | (60) | (46) | (24) | (55) | 3 | (13) | (25) | (18) | (20) |
| Net income | – | – | (46) | (24) | (55) | 3 | (13) | (25) | (18) | (20) |
| Net income to common shareholders | (62) | (60) | (46) | (24) | – | – | – | – | – | – |